SCHEMBL311760

SCHEMBL311760

O=c1cc(-c2ccc(O)nc2)oc2cccc(O)c12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 12/20 0.68
CYP3A4 P08684 4/20 0.68
MAPT P10636 4/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
MAPK1 P28482 2/20 0.68
RAF1 P04049 1/20 0.68
HPGD P15428 1/20 0.68
ALOX15 P16050 2/20 0.66
KDM4E B2RXH2 1/20 0.66
ALOX5 P09917 1/20 0.66
CYP2C9 P11712 1/20 0.66
ALOX12 P18054 1/20 0.66
CYP2C19 P33261 1/20 0.66
RECQL P46063 1/20 0.66
HSD17B10 Q99714 1/20 0.66
IP6K2 Q9UHH9 1/20 0.66
POLH Q9Y253 1/20 0.66
CYP1A1 P04798 2/20 0.65
CYP1A2 P05177 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311199 0.82 TNKS (0.67) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL157490 0.81 AR (1.00) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL9199822 0.81 AR (0.69) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL6094870 0.81 CYP3A4 (0.85) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL3817277 0.80 CYP3A4 (1.00) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL30591245 0.80 CYP3A4 (1.00) ARCYP3A4MAPTMEN1KMT2A
SCHEMBL312103 0.80 CYP19A1 (0.48) CYP3A4MAPTMEN1KMT2AMAPK1
5-Hydroxyflavone SCHEMBL158303 0.79 AR (1.00) ARCYP3A4MAPTMEN1KMT2A
5-Hydroxyflavone SCHEMBL2390993 0.79 AR (1.00) ARCYP3A4MAPTMEN1KMT2A
5-Hydroxyflavone SCHEMBL30630415 0.79 AR (1.00) ARCYP3A4MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 AR 2406/4885CYP3A4 1730/4885MAPT 2914/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 AR 2406/4885CYP3A4 1730/4885MAPT 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.